S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Stock market today: Wall Street dips to send S&P 500 to its longest losing streak since January
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom

Tenaya Therapeutics (TNYA) Competitors

$4.30
-0.16 (-3.59%)
(As of 04/17/2024 ET)

TNYA vs. MGTX, TCRX, AURA, PGEN, AVXL, CRBU, JSPR, HUMA, SOPH, and IVVD

Should you be buying Tenaya Therapeutics stock or one of its competitors? The main competitors of Tenaya Therapeutics include MeiraGTx (MGTX), TScan Therapeutics (TCRX), Aura Biosciences (AURA), Precigen (PGEN), Anavex Life Sciences (AVXL), Caribou Biosciences (CRBU), Jasper Therapeutics (JSPR), Humacyte (HUMA), SOPHiA GENETICS (SOPH), and Invivyd (IVVD). These companies are all part of the "medical" sector.

Tenaya Therapeutics vs.

MeiraGTx (NASDAQ:MGTX) and Tenaya Therapeutics (NASDAQ:TNYA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, community ranking, dividends, profitability, media sentiment, valuation, institutional ownership, earnings and analyst recommendations.

MeiraGTx has a beta of 1.29, indicating that its stock price is 29% more volatile than the S&P 500. Comparatively, Tenaya Therapeutics has a beta of 2.6, indicating that its stock price is 160% more volatile than the S&P 500.

Tenaya Therapeutics has a net margin of 0.00% compared to Tenaya Therapeutics' net margin of -599.47%. MeiraGTx's return on equity of -69.94% beat Tenaya Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
MeiraGTx-599.47% -114.33% -42.56%
Tenaya Therapeutics N/A -69.94%-59.80%

MeiraGTx has higher revenue and earnings than Tenaya Therapeutics. MeiraGTx is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MeiraGTx$14.02M24.05-$84.03M-$1.47-3.57
Tenaya TherapeuticsN/AN/A-$124.08M-$1.67-2.57

MeiraGTx received 164 more outperform votes than Tenaya Therapeutics when rated by MarketBeat users. However, 74.19% of users gave Tenaya Therapeutics an outperform vote while only 71.10% of users gave MeiraGTx an outperform vote.

CompanyUnderperformOutperform
MeiraGTxOutperform Votes
187
71.10%
Underperform Votes
76
28.90%
Tenaya TherapeuticsOutperform Votes
23
74.19%
Underperform Votes
8
25.81%

MeiraGTx presently has a consensus price target of $25.67, suggesting a potential upside of 388.89%. Tenaya Therapeutics has a consensus price target of $15.40, suggesting a potential upside of 258.14%. Given Tenaya Therapeutics' higher possible upside, equities research analysts clearly believe MeiraGTx is more favorable than Tenaya Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MeiraGTx
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Tenaya Therapeutics
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
3.00

67.5% of MeiraGTx shares are owned by institutional investors. Comparatively, 90.5% of Tenaya Therapeutics shares are owned by institutional investors. 9.7% of MeiraGTx shares are owned by company insiders. Comparatively, 33.8% of Tenaya Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Tenaya Therapeutics had 4 more articles in the media than MeiraGTx. MarketBeat recorded 4 mentions for Tenaya Therapeutics and 0 mentions for MeiraGTx. Tenaya Therapeutics' average media sentiment score of 1.89 beat MeiraGTx's score of 0.86 indicating that MeiraGTx is being referred to more favorably in the media.

Company Overall Sentiment
MeiraGTx Very Positive
Tenaya Therapeutics Positive

Summary

Tenaya Therapeutics beats MeiraGTx on 9 of the 16 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TNYA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TNYA vs. The Competition

MetricTenaya TherapeuticsBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$337.64M$2.67B$4.76B$7.41B
Dividend YieldN/A2.28%5.42%3.97%
P/E Ratio-2.5738.99255.8418.47
Price / SalesN/A322.262,450.3087.81
Price / CashN/A145.5547.8235.32
Price / Book2.103.894.624.20
Net Income-$124.08M-$41.70M$101.98M$212.26M
7 Day Performance-4.02%-5.87%-4.70%-4.42%
1 Month Performance-13.57%-7.24%-4.45%-3.47%
1 Year Performance44.30%2.04%10.13%4.35%

Tenaya Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MGTX
MeiraGTx
4.3532 of 5 stars
$5.41
-1.1%
$25.67
+374.4%
+1.9%$347.43M$14.02M-3.68419Positive News
TCRX
TScan Therapeutics
1.8279 of 5 stars
$7.13
-7.3%
$12.50
+75.3%
+225.6%$341.38M$21.05M-3.77154Analyst Report
News Coverage
AURA
Aura Biosciences
1.7224 of 5 stars
$7.26
-3.8%
$21.00
+189.3%
-16.6%$359.37MN/A-3.7888Short Interest ↑
PGEN
Precigen
3.1054 of 5 stars
$1.36
-2.9%
$10.00
+635.3%
+29.5%$338.53M$6.22M-3.49202Positive News
AVXL
Anavex Life Sciences
3.3033 of 5 stars
$4.12
-2.6%
$40.00
+870.9%
-47.7%$338.29MN/A-7.6340Short Interest ↑
CRBU
Caribou Biosciences
1.4848 of 5 stars
$4.01
-1.5%
$22.50
+461.1%
-12.4%$362.18M$34.48M-2.77158Positive News
JSPR
Jasper Therapeutics
2.4021 of 5 stars
$24.17
-8.1%
$64.17
+165.5%
+66.7%$364MN/A-3.9045
HUMA
Humacyte
1.635 of 5 stars
$3.06
+6.6%
$8.00
+161.4%
-5.8%$364.39M$1.57M-2.86164Short Interest ↑
Gap Up
SOPH
SOPHiA GENETICS
1.4959 of 5 stars
$4.98
+2.5%
$8.00
+60.6%
+14.0%$324.85M$62.37M-4.08430
IVVD
Invivyd
2.6958 of 5 stars
$2.70
-3.9%
$11.33
+319.8%
+130.8%$321.89MN/A-1.4984Gap Down

Related Companies and Tools

This page (NASDAQ:TNYA) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners